Medpace opines that Medical Consulting will add strategic expertise in terms of providing centralized European hubs for regulatory submissions and approvals as well as drug safety management and reporting. Medical Consulting is led by Dr med Ursula Schlichtiger, general manager, and a research professional with extensive experience in clinical development, regulatory affairs, and pharmacovigilance.
Dr August Troendle, president and CEO of Medpace, said: “I am pleased to have Dr Schlichtiger join the Medpace team to support our growing presence in the European drug development market as managing director and senior director of medical and regulatory affairs, Europe. Dr Schlichtiger has built a reputation in Europe as a distinguished professional having founded Medical Consulting in 1989 and building the company into an organization widely recognized for their successful interaction with European governmental agencies.”
The integration of Medical Consulting will begin immediately and is likely to be completed by mid 2010. The leaders at Medical Consulting will continue in their respective roles as businesses integrate, said the company.